Journal of Vaccine Research 2024, Vol.14, No.4, 170-182 http://medscipublisher.com/index.php/jvr 180 Global collaboration and sustained funding will be essential to support these research efforts and ensure that new vaccines are accessible to those who need them most. Furthermore, the integration of dengue vaccination into broader public health initiatives, alongside vector control and surveillance, will be vital in achieving long-term control of dengue. As the scientific community continues to innovate and build on existing knowledge, the goal of a universally effective dengue vaccine that can be safely administered across all populations is within reach. Acknowledgments The author expresses gratitude to the two anonymous peer reviewers for their feedback. Conflict of Interest Disclosure The author affirms that this research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest. References Biswal S., Reynales H., Sáez-Llorens X., López P., Borja-Tabora C., Kosalaraksa P., Sirivichayakul C., Watanaveeradej V., Rivera L., Espinoza F., Fernando L., Dietze R., Luz K., Cunha R., Jimeno J., López-Medina E., Borkowski A., Brose M., Rauscher M., Lefevre I., Bizjajeva S., Bravo L., and Wallace D., 2019, Efficacy of a tetravalent dengue vaccine in healthy children and adolescents, New England Journal of Medicine, 381(21): 2009-2019. https://doi.org/10.1056/NEJMoa1903869 PMid:31693803 Capeding M., Tran N., Hadinegoro S., Ismail H., Chotpitayasunondh T., Chua M., Luong C., Rusmil K., Wirawan D., Nallusamy R., Pitisuttithum P., Thisyakorn U., Yoon I., Vliet D., Langevin E., Laot T., Hutagalung Y., Frago C., Boaz M., Wartel T., Tornieporth N., Saville M., and Bouckenooghe A., 2014, Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial, The Lancet, 384(9951): 1358-1365. https://doi.org/10.1016/S0140-6736(14)61060-6 PMid:25018116 da Silveira L.T.C., Tura B., and Santos M., 2019, Systematic review of dengue vaccine efficacy, BMC Infectious Diseases, 19: 1-8. https://doi.org/10.1186/s12879-019-4369-5 PMid:31455279 PMCid:PMC6712597 de Silva A., and White L., 2023, Immunogenicity of a live dengue vaccine (TAK-003), The Journal of Infectious Diseases, 227(1): 163-164. https://doi.org/10.1093/infdis/jiac424 PMid:36285800 PMCid:PMC10310987 Deng S.Q., Yang X., Wei Y., Chen J.T., Wang X.J., and Peng H.J., 2020, A review on dengue vaccine development, Vaccines, 8(1): 63. https://doi.org/10.3390/vaccines8010063 PMid:32024238 PMCid:PMC7159032 Flacco M.E., Bianconi A., Cioni G., Fiore M., Calò G.L., Imperiali G., Orazi V., Tiseo M., Troia A., Rosso A., and Manzoli L., 2024, Immunogenicity, safety and efficacy of the dengue vaccine TAK-003: a meta-analysis, Vaccines, 12(7): 770. https://doi.org/10.3390/vaccines12070770 PMid:39066408 PMCid:PMC11281463 Flasche S., Jit M., Rodríguez-Barraquer I., Coudeville L., Recker M., Koelle K., Milne G., Hladish T., Perkins T., Cummings D., Cummings D., Dorigatti I., Laydon D., España G., Kelso J., Longini I., Lourenço J., Pearson C., Reiner R., Mier-y-Teran-Romero L., Vannice K., and Ferguson N., 2016, The long-term safety, public health impact, and cost-effectiveness of routine vaccination with a recombinant, live-attenuated dengue vaccine (Dengvaxia): a model comparison study, PLoS Medicine, 13(11): e1002181. https://doi.org/10.1371/journal.pmed.1002181 PMid:27898668 PMCid:PMC5127514 Guy B., 2018, Which dengue vaccine approach is the most promising, and should we be concerned about enhanced disease after vaccination? questions raised by the development and implementation of dengue vaccines: example of the sanofi pasteur tetravalent dengue vaccine, Cold Spring Harbor Perspectives in Biology, 10(6): a029462. https://doi.org/10.1101/cshperspect.a029462 PMid:28716892 PMCid:PMC5983191 Guy B., Barrère B., Malinowski C., Saville M., Teyssou R., and Lang J., 2011, From research to phase III: preclinical, industrial and clinical development of the sanofi pasteur tetravalent dengue vaccine, Vaccine, 29(42): 7229-7241. https://doi.org/10.1016/j.vaccine.2011.06.094 PMid:21745521 Guy B., Lang J., Saville M., and Jackson N., 2016, Vaccination against dengue: challenges and current developments, Annual Review of Medicine, 67(1): 387-404. https://doi.org/10.1146/annurev-med-091014-090848 PMid:26515983
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==